UK markets closed

Roche Holding AG (0QOK.IL)

IOB - IOB Delayed price. Currency in CHF
Add to watchlist
283.65+10.55 (+3.86%)
At close: 06:28PM GMT
Full screen
Previous close273.10
Bid276.60 x N/A
Ask289.70 x N/A
Day's range275.60 - 284.05
52-week range272.10 - 404.10
Avg. volume542,654
Market cap233.055B
Beta (5Y monthly)0.21
PE ratio (TTM)16.03
EPS (TTM)17.69
Earnings dateN/A
Forward dividend & yield9.30 (3.22%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Zacks

    Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal

    Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.

  • Reuters

    Roche warns 2023 profits will fall on $5 billion COVID sales hit

    Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry's years-long pandemic boost is ebbing. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the Swiss pharmaceuticals and diagnostics company said in a statement. COVID-related sales, mainly from lab testing and antibody treatment Ronapreve, are seen falling by 5 billion Swiss francs ($5.5 billion) for the full year, it said.

  • Globe Newswire

    [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee

    Basel, 2 February 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Board of Directors has made the following appointments: Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO Roche Pharmaceuticals based in Basel, Switzerland effective March 2023 and will become a member of the Corporate Executive Committee. At the same time, Levi Garraway, Chief Medical Officer and Executive Vice President, Global Product Development, based